Keith T Hogan

Title: Innovations of Keith T Hogan

Introduction

Keith T Hogan is a notable inventor based in Dorval, Canada. He has made significant contributions to the field of radiopharmaceuticals, particularly in the development of chelating ligands. With a total of 3 patents, his work has advanced the selective detection and treatment of tumors.

Latest Patents

Hogan's latest patents include innovative N3S2 chelating ligands that can be radiolabelled with technetium (Tc) or rhenium (Re). These ligands are particularly useful for radiolabeling peptides, especially somatostatin derivatives, which are valuable for the selective detection or treatment of tumors with somatostatin receptors. His work on technetium or rhenium radionuclide labelled chelate-hexapeptide complexes has further enhanced the capabilities of radioimaging agents and radiopharmaceuticals for tumor treatment.

Career Highlights

Throughout his career, Keith T Hogan has worked with prominent companies such as Merck Frosst Canada, Inc. and Merck & Co., Inc. His experience in these organizations has contributed to his expertise in the field of pharmaceuticals and radiochemistry.

Collaborations

Hogan has collaborated with notable professionals in his field, including Richard J Flanagan and Jean-Marc DuFour. These collaborations have likely enriched his research and development efforts.

Conclusion

Keith T Hogan's contributions to the field of radiopharmaceuticals through his innovative patents and collaborations highlight his importance as an inventor. His work continues to impact the medical field, particularly in cancer detection and treatment.